More News of Interest

SOLIUS Announces Investment from Human Longevity Inc. to Support Mission of Improving Health, Performance, and Longevity

May 13, 2020

SOLIUS, a developer of innovative light therapy technologies focused on mitigating vitamin D deficiency, today announced investment from Human Longevity, Inc. (HLI) into its Series B financing.

The SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light. Vitamin D has a wide range of impact on systemic health, and supports physical, mental and immune function. SOLIUS delivers safe and effective light therapy using a personalized dosing system while filtering out nearly all other ultraviolet light. The SOLIUS technology can produce 10x more vitamin D than the sun, using 100x less ultraviolet energy. This technology is also an effective solution for at risk populations unable to absorb vitamin D orally.

HIL is a pioneer and leader in the delivery of data-driven, predictive precision health intelligence. Wei-Wu He, PhD, Executive Chairman, HLI stated: “We are excited to invest in SOLIUS as its mission is to provide the benefits of the sun without the harmful rays to unlock the healing powers of the human body. Investing in SOLIUS is another example of HLI’s expertise in aggregating and leveraging technologies designed to demonstrably increase health, performance and lifespan. I welcome SOLIUS to our emerging ecosystem of longevity and performance-focused companies.”

Bob Wise, SOLIUS CEO, said “Humans need sun exposure to stay healthy, and the benefits of the sun cannot be fully replicated with hormone replacement, such as oral vitamin D supplements. We are excited to partner with HLI in developing technologies that prevent disease and improve human health.”

Latest Posts

spot_img

Don't Miss

Stay on top - Get Medical Device News Magazine daily news in your inbox

Enter your email address:

Delivered by FeedBurner